A Phase 1 Study of LY2784544 in Patients With JAK2 V617F-Positive Myeloproliferative Disorders.
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 20 May 2017
At a glance
- Drugs Gandotinib (Primary)
- Indications Essential thrombocythaemia; Myelofibrosis; Polycythaemia vera
- Focus Adverse reactions; Therapeutic Use
- Sponsors Eli Lilly
- 18 May 2017 Planned End Date changed from 1 Jun 2017 to 1 Aug 2018.
- 09 Dec 2016 Planned End Date changed from 1 Dec 2016 to 1 Jun 2017.
- 05 Oct 2016 Planned End Date changed from 1 Aug 2016 to 1 Dec 2016.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History